Ocular Therapeutix, Inc. (OCUL)
NGM · Healthcare · Biotechnology
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 14.5M | 13.2M | 10.8M | 13.5M |
| Gross Profit | 12.8M | 11.7M | 9.5M | 11.5M |
| Operating Income | (68.7M) | (69.8M) | (93.3M) | (82.1M) |
| Net Income | (69.4M) | (64.7M) | (88.6M) | (78.8M) |
| Diluted EPS | $-0.38 | $-0.29 | $-0.40 | $-0.35 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 51.5M | 58.4M | 63.7M | 52.0M |
| Gross Profit | 47.0M | 53.2M | 58.1M | 45.4M |
| Operating Income | (78.7M) | (82.4M) | (171.8M) | (270.0M) |
| Net Income | (71.0M) | (80.7M) | (193.5M) | (265.9M) |
| Diluted EPS | $-0.97 | $-1.02 | $-1.22 | $-1.42 |